A Study of LX211 in Clinically Quiescent Non-infectious Intermediate, Anterior and Intermediate, Posterior or Pan-Uveitis

NCT00404742 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

232

Enrollment

INDUSTRY

Sponsor class

Conditions

Uveitis, Posterior
Uveitis, Intermediate
Panuveitis

Interventions

DRUG: Placebo
DRUG: LX211
DRUG: LX211
DRUG: LX211

Sponsor

Lux Biosciences, Inc.